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1. Introduction
  Non-small cell lung cancer (NSCLC) is one of the 
malignant tumors with the highest incidence and mortality. 
Chemotherapy is the main treatment, but different 
individuals have different chemotherapy response and 
prognosis. The follow-up showed that the success or 
failure of the initial chemotherapy play an extremely 
important role to the effective rate and prolong survival 
time. Human equilibrative nucleoside transporter 1 (hENT1) 
is the important carrier which transport gemcitabine into 
the cell, and excision repair cross complementing gene l 
(ERCC1) is extremely important DNA repair factors. This 
study established subcutaneous planting in 30 nude mice, 
selected mice with successful implanted cancer cells and 
then carried out anti-tumor experiment combined with 
chemotherapy, and also analyzed the relations between the 
hENT1 and ERCC1 mRNA expression levels and the efficacy 
of gemcitabine chemotherapy, provide a basis for analyzing 
individual chemosensitivity.
2. Materials and methods
2.1. Experimental animals and agents
  Sixty nude mice were selected, 4 to 8 week old, weighing 
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20-25 g, provided by XX University Experimental Animal 
Center. Animals were kept in the isolation box of the 
standard laboratory. Lewis lung cancer cell line (LLC) 
was purchased from American Type Culture collection 
Stock (ATCC). GEM, DDP was purchased from Simcere 
Company. Total RNA extraction reagent Trizol-A in tissue 
were purchased from Omega Company. cDNA synthesis kit 
were purchased from Takara, SYBR Green 栺 fluorescence 
quantitation kit were also purchased from TaKaRa, pGM-T 
vector kit were purchased from Shanghai Sangon Company. 
PCR instrument was purchased from the British Techne 
Company, gel imaging system was purchased from the Sigma 
Company.
2.2. Preparation and selection of samples
  The NCI-H460 cells were inoculated into RPMI-1640 
culture medium with 10% FBS, cultured in 37 曟 insulation 
incubator. Cells were suspended when they were grown to 
about 50%-60%. After ether anesthesia, 0.5 mL NCI-H460 
prepared cell suspension was inoculated subcutaneously in 
mice.
2.3. Animal grouping and treatment programs
  
  The tumor formation standard was 200-300 mm, 52 mice 
with successful inoculation; the success rate was 86.7%. 
There are 4 experimental groups, each group with 12 mice 
of successful inoculation. DDP group received DDP (2.5 mg/
kg) 2 times/week injection in tail vein for 2 weeks; GEM 
group received GEM (50 mg/kg) 2 times/week intraperitoneal 
injection for 2 weeks; The clinical medicine and course of 
treatment in GEM + DDP group were the same as the GEM 
group and DDP group; Normal saline (NS) served as the 
control group.
2.4. Detection index
  The length and width of the tumor were measured with a 
vernier caliper every 2 d. the Tumor volume was record and 
calculated as follows: [TV (mm3) = 0.52暳L暳W]. Relative 
tumor volume (RTV) = 15 days TV/1 Day TV. Relative tumor 
proliferation rate (T/C) = experimental groups RTV/control 
group RTV. 
 
2.5. Primer design and synthesis
  The sequence of hENTl, ERCC1 and 毬-actin were as 
follow:
hENTl upstream primer: 5’-TGTTTCCAGCCGTGACT-3’, 
downstream primer: 5’-CAGGCCACATGAATACAG-3’;
ERCC1 upstream primer: 5’-CTGGGAATTTGGCGACGTAA-3’, 
downstream primer: 5’-ATGGATGTAGTCTGGGTGCAG-3 ’;
毬-actin upstream primer: 5’-GCGAGAAGATGACCCAGATC-3, 
downstream primer 5 ’-GGATAGCAACGCCTGGATAG-3’.
2.6. Real-time quantitative fluorescent PCR
  Two mice were sacrificed in each group 1 d after the 
treatment, and the tumor tissues were peeled and then 
received hENTl, ERCC1 testing. The plasmid standard 
of the  hENTl, ERCC1 and housekeeping gene (毬-actin) 
were diluted into 6 concentration groups with geometric 
proportion, and then real-time fluorescence quantitative 
PCR was carried out.
hENTl reaction conditions: 95 曟 60 s 1 cycle, 95 曟 15 s,
61 曟 60 s 40 cycles, 95 曟 60 s, 60 曟 30 s, 95 曟 30 s 1 
cycles. 
ERCC1 reaction conditions: 95 曟 60 s 1 cycle, 95 曟 20 s,
60 曟 60 s 40 cycles, 95 曟 60 s, 60 曟 30 s, 95 曟 30 s 1 
cycles.
  PCR products were identified by gel eletrophoresis, the 
mRNA absorbance values of hENTl, ERCC1 mRNA were 
standardized by internal reference 毬-actin optical density 
and the relative content of the hENTl, ERCC1 mRNA 
expression were obtained.
2.7. Survival time evaluation
  The rest mice were used for survival observation. The 
time of inoculated with LLC cells was the starting point of 
observation, and the death of the mice in 4 groups was the 
end point.
2.8. Statistical analysis
  All of the data were analyzed by SPSS 14. 0 statistics 
software, and the measurement data were expressed as mean
暲SD values. One-Way ANOVA and t-test were applied in 
the comparison between groups. Log-rank test was used 
for survival analysis. P <0.05 was considered as statistical 
significance.
 
3. Results
3.1. Comparison of the tumor volume
  After 1 d of the treatment, tumor volume of GEM + DDP 
group was (1376.5暲189.6) mm3, while tumor volume of 
NS group, DDP group and the GEM group were (3 275.0暲
472.7), (2 643.8暲342.7), (2 436.6暲334.2) mm3, respectively. 
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Compared with NS group,the tumor volume of GEM group, 
DDP group, GEM + DDP group were significantly reduced 
(P<0. 05). Compared with the GEM group and the DDP group, 
the tumor volume of GEM + DDP group was significantly 
reduced (P<0.05). The TV, RTV and T/C (%) of the DDP group 
were similar to the GEM group. There was no significant 
difference (P>0.05) (Table 1).
Table 1 
Comparison of the tumor volume in each group.
Groups TV(mm3) RTV T/C(%)
NS 3 275.0暲472.7 7.5暲2.0 100.0
DDP 2 643.8暲342.7* 4.7暲1.4*   64.3*
GEM 2 436.6暲334.2* 4.5暲1.3*   62.4*
GEM+DDP 1 376.5暲189.6*吟○ 3.2暲1.0*吟啄   45.8*吟啄
Note: Compared with NS group, * P<0. 05; compared with DDP group, 
吟P<0. 05; compared with GEM, 啄P<0. 05.
3.2. Survival time
  In NS group, the mice all died after 52 d of LLC inoculation; 
In DDP group, there were 6 survived after 52 d of LLC 
inoculation (60.0%), but the mice all died after 59 d. 
  In GEM group, there were 6 survived after 52 d of LLC 
inoculation (60.0%), but the mice all died after 60 d. In 
GEM+DDP group, there were 8 survived after 56 d of LLC 
inoculation (60.0%), but the mice all died after 78 d. There 
were no obvious differences in the survival time between 
the DDP group or between the GEM group and NS group (P> 
0.05), while the time of GEM + ES group was significantly 
longer (P<0.05); compared with the GEM group and ES group, 
the GEM + ES group had significantly longer survival period 
(P<0.05).
3.3. Comparison of hENTl of the tumor tissue
  The hENTl in NS group, ES group, GEM group and GEM + 
ES group were (11.6暲1.6), (23.5暲2.2), (25.9暲2.3), (45.5暲5.4) 
pg/mL, respectively. Compared with NS group, the hENTl 
in the GEM group, DDP group and GEM + DDP group were 
significantly higher (P<0. 05). Compared with the other three 
groups, the hENTl of tumor tissue in the GEM + ES group was 
significantly higher (all P<0.05).  
3.4. Comparison of ERCC1 of the tumor tissue
  The ERCC1 expression of tumor tissues in the NS group, ES 
group, GEM group and GEM+ES group were (121.8暲8.2), (75.3
暲6.7), (72.4暲6.6), (37.4暲4.6) pg/mL, respectively. Compared 
with NS group, the ERCC1 in GEM group, DDP group, GEM + 
DDP group were decreased significantly (P<0. 05). Compared 
with the NS group, the ERCC1 expressions of GEM group, 
DDP group, GEM + DDP group were significantly decreased 
(all P<0.05).
 
4. Discussion
  Lung cancer is the main causes of death worldwide, which 
is divided into small cell lung cancer and non-small cell 
lung cancer, while non-small cell lung cancer accounts for 
80%[1,2]. The main treatments of non-small cell lung cancer 
were surgery, chemotherapy, radiotherapy and molecular 
targeted therapy at this stage. The study of Schiller[3] showed 
that the side effects of platinum-based joint program vary 
greatly. However, there was no significant difference in 
clinical efficacy. Gemcitabine has obvious advantages in 
treating PFS patients.
  Gemcitabine is a anticarcinogen which is a difluoro 
nucleoside antimetabolite. It can damage the cell replication, 
which is a water-soluble analogues of the deoxy cytidine. 
It is a substitute of inhibitory substrate to ribonucleotide 
reductase enzyme. This enzyme play an important role in 
the generation of the required deoxynucleotides during the 
process of DNA synthesis and repair. Therefore, find the 
related genes which can predict the efficacy of gemcitabine 
is become the research focus in clinical. In this study, we 
detected the mRNA expression of human equilibrative 
nucleoside transporter1(hENTl) and excision repair cross-
complementing gene1(ERCC1) by real-time quantitative 
PCR, and explore the correlation between them and the non-
small cell lung cancer and the efficacy and side effects of 
the gemcitabine.
  As a hydrophilic substance, gemcitabine require carriers 
to pass freely into the cell by diffusion. While hENTl is the 
mainnucleoside transporter protein which participate in 
the gemcitabine transmembrane transport processes, and 
it is positively correlated to the gemcitabine anti-tumor 
effect. The studies of Achiwa et al[4] suggest that the high 
expression of hENTl mRNA can increase the sensitivity of 
gemcitabine to NSCLC cell lines. The patients with hENTl 
positive protein expression also benefit significantly during 
gemcitabine therapy, hENTl can be a predicted molecules as 
the gemcitabine treatment in NSCLC.
  The conclusions of the study of Toffaloriol et al[5] are 
consistent with Achiwa et al. The siRNA method was used 
to reduce the hENTl mRNA expression levels of two lung 
cancer cell line A549, H1703, which can also lead to the 
significant increase in gemcitabine IC50. Our results show 
that the tumor TV, RTV and T/C were significantly reduced 
in the GEM + DDP group, the results show that the GEM + 
DDP chemotherapy effect is significant. Single drug therapy 
can significantly inhibit the tumor size and also significantly 
improved survival time. hENTlmRNA has a high expression 
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in the GEM + DDP chemotherapy group, and it has a low 
expression in the NS control group, which indicates the 
low expression of hENTlmRNA has a poor prognosis, 
while in the high expression group patients who received 
gemcitabine chemotherapy can benefit from the treatment. 
So the hENTl can be considered as a predictive indicator of 
chemosensitivity. The results were consentaneous with the 
experimental results of Rongrong et al[6].
  Some studies think that the efficacy of platinum-based 
chemotherapy was correlated to the ERCC1 expression[7]. 
The excision repairment of Cisplatin-DNA adducts were 
by the nucleotide excision repair pathway system. The 
ERCC1 gene, as an important member of protein nucleotide 
excision repair matrix, plays an important role during the 
process. The experimental results of Chen et al[8] show 
that compared to patients with high ERCC1 expression, 
patients with low ERCC1 expression has a longer survival 
time after receive the platinum-based chemotherapy. Most 
literature[9,10] showed that in advanced NSCLC, patients 
with high ERCC1 expression had a poor prognosis. The 
ERCC1mRNA expression levels in GEM group, DDP group, 
GEM + DDP group were significantly less than the control 
group, especially the GEM + DDP chemotherapy group. The 
results showed high ERCC1mRNA expression have poor 
prognosis, which suggested patients with low expression 
group were more sensitive to the gemcitabine chemotherapy 
drugs,and the chance of drug resistance were greater in 
patients with high ERCC1 expression in tumor tissue during 
the gemcitabine chemotherapy.
  In summary, this study indicates that patients with high 
hENTlmRNA expression and low ERCC1mRNA expression 
had a better efficacy and a longer survival time of NSCLC 
tumor during the gemcitabine chemotherapy. For patients 
who receive individualized postoperative adjuvant 
chemotherapy, can adopt the “based on molecular biology of 
tumor detection” to filter the suitability of gemcitabine plus 
platinum chemotherapy.
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